HUE055891T2 - A gonadotropint felszabadító hormon (GNRH) receptor antagonista kristályos formája és annak elõállítási módja - Google Patents

A gonadotropint felszabadító hormon (GNRH) receptor antagonista kristályos formája és annak elõállítási módja

Info

Publication number
HUE055891T2
HUE055891T2 HUE17869463A HUE17869463A HUE055891T2 HU E055891 T2 HUE055891 T2 HU E055891T2 HU E17869463 A HUE17869463 A HU E17869463A HU E17869463 A HUE17869463 A HU E17869463A HU E055891 T2 HUE055891 T2 HU E055891T2
Authority
HU
Hungary
Prior art keywords
preparation
crystalline form
receptor antagonist
method therefor
gnrh receptor
Prior art date
Application number
HUE17869463A
Other languages
English (en)
Inventor
Quanliang Zhang
Junlei Jia
Lin Bian
Xiaohui Gao
Original Assignee
Jiangsu Hengrui Medicine Co
Suncadia Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co, Suncadia Pharmaceuticals Co Ltd filed Critical Jiangsu Hengrui Medicine Co
Publication of HUE055891T2 publication Critical patent/HUE055891T2/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/26Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28Oxygen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HUE17869463A 2016-11-14 2017-11-13 A gonadotropint felszabadító hormon (GNRH) receptor antagonista kristályos formája és annak elõállítási módja HUE055891T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201610999743 2016-11-14

Publications (1)

Publication Number Publication Date
HUE055891T2 true HUE055891T2 (hu) 2022-01-28

Family

ID=62109467

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE17869463A HUE055891T2 (hu) 2016-11-14 2017-11-13 A gonadotropint felszabadító hormon (GNRH) receptor antagonista kristályos formája és annak elõállítási módja

Country Status (16)

Country Link
US (1) US10787451B2 (hu)
EP (1) EP3539545B1 (hu)
JP (1) JP2019535712A (hu)
KR (1) KR102516017B1 (hu)
CN (1) CN108778282B (hu)
AU (1) AU2017357332B2 (hu)
BR (1) BR112019009455A2 (hu)
CA (1) CA3040026A1 (hu)
DK (1) DK3539545T3 (hu)
ES (1) ES2887018T3 (hu)
HR (1) HRP20211379T1 (hu)
HU (1) HUE055891T2 (hu)
PL (1) PL3539545T3 (hu)
PT (1) PT3539545T (hu)
TW (1) TWI774704B (hu)
WO (1) WO2018086608A1 (hu)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202111907UA (en) * 2019-04-30 2021-11-29 Beijing Tide Pharmaceutical Co Ltd Solid form of diaminopyrimidine compound or hydrate thereof, preparation method therefor, and application thereof
CN117203209A (zh) * 2021-04-02 2023-12-08 江苏恒瑞医药股份有限公司 一种GnRH受体拮抗剂的结晶形式及其制备方法
CN117769424A (zh) * 2021-08-30 2024-03-26 江苏恒瑞医药股份有限公司 一种GnRH受体拮抗剂的结晶工艺

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008533025A (ja) 2005-03-07 2008-08-21 ワイス キノキサリンジヒドロハライド二水和物およびそのための合成方法
JPWO2010026993A1 (ja) 2008-09-03 2012-02-02 武田薬品工業株式会社 製剤における吸収性改善方法および吸収性が改善された製剤
TW201130854A (en) 2009-12-22 2011-09-16 Bayer Schering Pharma Ag Pyridinone derivatives and pharmaceutical compositions thereof
WO2012175514A1 (en) 2011-06-21 2012-12-27 Bayer Intellectual Property Gmbh Pyridinone derivatives and pharmaceutical compositions thereof
UY35058A (es) * 2012-09-28 2014-04-30 Takeda Pharmaceutical Método de producción de derivado de tienopirimidina
SI3064498T1 (sl) * 2013-10-30 2019-11-29 Shanghai hengrui pharmaceutical co ltd Derivati pirazolopirimidona ali pirolotriazona, postopki priprave le-teh in farmacevtske uporabe le-teh
CN104788435A (zh) * 2014-01-16 2015-07-22 江苏恒瑞医药股份有限公司 一种蛋白酪氨酸激酶抑制剂的二苯磺酸盐的i型结晶

Also Published As

Publication number Publication date
KR20190080915A (ko) 2019-07-08
JP2019535712A (ja) 2019-12-12
CN108778282B (zh) 2021-07-27
BR112019009455A2 (pt) 2019-07-30
AU2017357332A1 (en) 2019-05-09
KR102516017B1 (ko) 2023-03-30
PT3539545T (pt) 2021-09-06
US20190276455A1 (en) 2019-09-12
ES2887018T3 (es) 2021-12-21
TW201817734A (zh) 2018-05-16
TWI774704B (zh) 2022-08-21
AU2017357332B2 (en) 2021-10-28
CA3040026A1 (en) 2018-05-17
WO2018086608A1 (zh) 2018-05-17
US10787451B2 (en) 2020-09-29
EP3539545A4 (en) 2020-07-01
EP3539545A1 (en) 2019-09-18
HRP20211379T1 (hr) 2021-12-10
PL3539545T3 (pl) 2022-01-10
CN108778282A (zh) 2018-11-09
EP3539545B1 (en) 2021-08-11
DK3539545T3 (da) 2021-09-27

Similar Documents

Publication Publication Date Title
HK1250710A1 (zh) 用於製備雄激素受體拮抗劑及其中間體的方法
IL253360A0 (en) New crystalline forms of neratinib malate and a process for their preparation
IL284005A (en) Glucocorticoid receptor inhibitors
LT3495352T (lt) Androgeno receptoriaus antagonisto kristalinės formos, paruošimo būdas ir jų panaudojimas
PT3411378T (pt) Formas cristalinas de monofumarato de tenofovir alafenamida
LT3327012T (lt) Bilastino kristalinės formos ir jų gamybos būdai
PT3539545T (pt) Forma cristalina de antagonista do recetor de gnrh e método para a preparação da mesma
EP3313396A4 (en) G-PROTEIN-COUPLED RECEPTOR CINASE INHIBITORS AND METHOD OF USE THEREOF
HK1250163A1 (zh) 作為5-氧代-ete受體拮抗劑的吲哚類似物及其使用方法
EP3134092A4 (en) Pharmaceutical salts of an orexin receptor antagonist
HK1247105A1 (zh) Mu類鴉片受體拮抗劑與類鴉片藥劑的組合劑型
HUE050459T2 (hu) Androgénreceptor-gátló kristályformája és annak elõállítási eljárása
EP3336088A4 (en) CRYSTALLINE FORM OF THE OREXIN RECEPTOR ANTAGONIST COMPOUND, PREPARATION METHOD AND APPLICATION THEREOF
EP3674294C0 (en) N-FORMYL VORTIOXETINE, METHOD FOR PREPARING IT AND SOLID PREPARATION OF VORTIOXETINE
TH1501006213A (th) รูปแบบยาของโพรเจสเทอโรนรีเซปเตอร์แอนตะกอนิสต์